Syneron Medical LtdFind Ratings Reports
SYNERON MEDICAL LTD's gross profit margin for the second quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. SYNERON MEDICAL LTD has strong liquidity. Currently, the Quick Ratio is 1.86 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 7.63% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||74.97||73.51|
|Net Income ($mil)||0.98||-0.3|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||68.35||79.25|
|Total Assets ($mil)||279.33||304.53|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||54.22||55.51|
|Return on Assets||-1.45||-1.79|
|Return on Equity||-1.95||-2.43|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||35.28||36.75|
|Div / share||0.0||0.0|
|Book value / share||5.88||6.11|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||138046.0||87748.0|
HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 1.34 indicates a discount versus the S&P 500 average of 2.73 and a significant discount versus the industry average of 4.92. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, SYNERON MEDICAL LTD proves to trade at a discount to investment alternatives within the industry.
|ELOS NM||Peers 45.70||ELOS 51.31||Peers 28.04|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ELOS's P/E is negative making this valuation measure meaningless.
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ELOS is trading at a significant premium to its peers.
|ELOS 17.44||Peers 24.12||ELOS NA||Peers 0.89|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
ELOS is trading at a premium to its peers.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ELOS 1.34||Peers 4.92||ELOS 26.67||Peers 21.73|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ELOS is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
ELOS is expected to have an earnings growth rate that exceeds its peers.
|ELOS 0.97||Peers 10.46||ELOS 4.94||Peers 18.86|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ELOS is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
ELOS significantly trails its peers on the basis of sales growth